EUVIMEDEUVIMED entdecken
Crossref

Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition

Juan M Roldán-Romero, Carlos Valdivia, Maria Santos, Javier Lanillos, Pablo Maroto, Georgia Anguera, Bruna Calsina, Angel Martinez-Montes, María Monteagudo, Sara Mellid, Luis J Leandro-García, Cristina Montero-Conde iD und 5 weitere

International Journal of Cancer · 15.09.2023 · 153 (6) · 1300-1312

DOI: 10.1002/ijc.34575 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2023-06. Verfasst von Juan M Roldán-Romero und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Ministerio de Ciencia e Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mammalian target of rapamycin (mTOR) is a central regulator of mammalian metabolism and physiology. Aberrant hyperactivation of the mTOR pathway promotes tumor growth and metastasis, and can also promote tumor resistance to chemotherapy and cancer drugs; this makes mTOR an attractive cancer therapeutic target. mTOR inhibitors have been approved to treat cancer; however, the mechanisms underlying drug sensitivity remain poorly understood. Here, whole exome sequencing of three chromophobe renal cell carcinoma (chRCC) patients with exceptional mTOR inhibitor sensitivity revealed that all three patients shared somatic mutations in the deubiquitinase gene USP9X . The clonal characteristics of the mutations, which were amassed by studying multiple patients' primary and metastatic samples from various years, together with the low USP9X mutation rate in unselected chRCC series, reinforced a causal link between USP9X and mTOR inhibitor sensitivity. Rapamycin treatment of USP9X‐depleted HeLa and renal cancer 786‐O cells, along with the pharmacological inhibition of USP9X, confirmed that this protein plays a role in patients' sensitivity to mTOR inhibitors. USP9X was not found to exert a direct effect on mTORC1, but subsequent ubiquitylome analyses identified p62 as a direct USP9X target. Increased p62 ubiquitination and the augmented rapamycin effect upon bortezomib treatment, together with the results of p62 and LC3 immunofluorescence assays, suggested that dysregulated autophagy in USP9X‐depleted cells can have a synergistic effect with mTOR inhibitors. In summary, we show that USP9X constitutes a potential novel marker of sensitivity to mTOR inhibitors in chRCC patients, and represents a clinical strategy for increasing the sensitivity to these drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansCell Line, TumorDeubiquitinating EnzymesMTOR InhibitorsSirolimusTOR Serine-Threonine KinasesUbiquitin Thiolesterase

Stichwörter der Autor:innen

USP9XmTOR signalingp62renal cell carcinomaubiquitination

Substanzen

Deubiquitinating EnzymesMTOR InhibitorsSirolimusTOR Serine-Threonine KinasesUbiquitin ThiolesteraseUSP9X protein, humanMTOR protein, human

Autor:innen und Institutionen

  • Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Spain.
  • Monoclonal Antibodies Core Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Structural Biology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

ORCID-Profile: Cristina Montero-Conde, Cristina Rodriguez-Antona

Förderung

  • Ministerio de Ciencia e Innovación

Zitieren

APA

Roldán-Romero, J. M., Valdivia, C., Santos, M., Lanillos, J., Maroto, P., Anguera, G., Calsina, B., Martinez-Montes, A., Monteagudo, M., Mellid, S., Leandro-García, L. J., Montero-Conde, C., Cascón, A., Roncador, G., Coloma, J., Robledo, M., & Rodriguez-Antona, C. (2023). Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition. International Journal of Cancer, 153(6), 1300-1312. https://doi.org/10.1002/ijc.34575

Vancouver

Roldán-Romero JM, Valdivia C, Santos M, Lanillos J, Maroto P, Anguera G, et al. Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition. International Journal of Cancer. 2023;153(6):1300-1312. doi:10.1002/ijc.34575

BibTeX
@article{RoldnRomero2023,
  author = {Roldán-Romero, Juan M and Valdivia, Carlos and Santos, Maria and Lanillos, Javier and Maroto, Pablo and Anguera, Georgia and Calsina, Bruna and Martinez-Montes, Angel and Monteagudo, María and Mellid, Sara and Leandro-García, Luis J and Montero-Conde, Cristina and Cascón, Alberto and Roncador, Giovanna and Coloma, Javier and Robledo, Mercedes and Rodriguez-Antona, Cristina},
  title = {Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition},
  journal = {International Journal of Cancer},
  year = {2023},
  volume = {153},
  number = {6},
  pages = {1300--1312},
  doi = {10.1002/ijc.34575}
}
Kostenlos starten →